New interview released with Daejin Abidoye, Medical Director from Roche-Genentech in the run up to his keynote address at Cancer Vaccines 2016 next month.
"As a Medical Director in Clinical Development, I help oversee the Genitourinary (GU) Malignancies program for our Immuno-Oncology Franchise. Our lead molecule, Atezolizumab, is a humanized engineered monoclonal antibody that selectively targets PD-L1 and has shown clinical activity in various solid tumor malignancies. As the Clinical Lead for Atezolizumab in Urothelial Cancer, I have led the clinical team through the growth of a comprehensive product development program in urothelial cancer, to the recent approval of atezolizumab for metastatic urothelial cancer (mUC) in the United States."
The full interview is available at http://www.smi-online.co.uk/goto/2016cancervaccinesevent.asp#tab_downloads
Looks good from here.
$120 target possibly.
Genentech Urges Shareholders to Take No Action With Respect to Unsolicited Tender Offer From Roche
The special committee of the Board of Directors of Genentech, Inc. (NYSE:DNA) today urged Genentech shareholders to take no action at this time with respect to the tender offer commenced by Roche to acquire all of the outstanding shares of Genentech stock not owned by Roche at a price of $86.50 in cash per share. Currently, Roche owns approximately 55.8% of the outstanding shares of Genentech.
Got in at 78 (before Cramer's pump)hehe
Roche Bids to Buy Remaining Genentech Shares for $43.7 Billion
By Dermot Doherty
July 21 (Bloomberg) -- Roche Holding AG, the world's biggest maker of cancer drugs, offered to buy the rest of Genentech Inc. for $43.7 billion to gain the U.S. company that supplied it with the best-selling Avastin and Herceptin tumor medicines.
Investors in Genentech would get $89 a share in cash, 8.8 percent more than the July 18 closing price, the Basel-based drugmaker said today. Roche already owns 56 percent of the South San Francisco, California-based company.
Roche today reported a decline in first-half profit as sales of the Tamiflu pill fell because governments stopped stockpiling the medicine that could slow an influenza pandemic. The purchase would be Roche's biggest ever and the combined company would generate more than $15 billion in annual sales. Roche shares declined the most since January on investor concerns it'll have to raise the bid for Genentech, the world's second-biggest biotechnology company.
``The transaction has positive and negative aspects,'' Rahn & Bodmer analyst Birgit Kulhoff said today in a note to investors. ``Roche can protect operating margins and EPS growth through this acquisition.'' The ``very low premium'' means that Roche either sees the prospects for Genentech ``very negatively, which would justify a low valuation, or the offer to Genentech shareholders will have to be raised.''
Roche fell as much as 3.7 percent to 173 Swiss francs and declined 5.7 francs, or 3.2 percent, at 10:54 a.m. in Zurich trading. The shares had decreased 8.2 percent this year, outperforming the Bloomberg Europe Pharmaceutical Index of 19 companies, which has declined 12 percent. Genentech rose 5 euros, or 10 percent, to 56.30 euros ($89.48) in German trading today.
`Unlikely to Succeed'
Genentech spokespeople Caroline Pecquet and Geoff Teeter didn't respond to out-of-office hours telephone calls and e- mailed requests for comment.
The offer is ``highly unlikely to succeed,'' at this level, Cazenove analysts James Millett and David Adlington wrote in a research note today. ``We would expect Roche will have to make a significantly higher offer if it is to acquire Genentech.''
First-half net income fell to 5.73 billion Swiss francs ($5.58 billion) from 5.86 billion francs a year earlier, Roche said today in a separate statement. Analysts surveyed by Bloomberg had a median profit estimate of 5.55 billion francs. Roche, which doesn't report quarterly profit, pushed up its earnings release from July 24.
Group sales decreased 3.6 percent in the first half to 22 billion francs. Revenue from Tamiflu declined 71 percent to 327 million francs.
Boost in Growth
Drugmakers are looking to boost growth with acquisitions as the U.S. pharmaceutical market, the world's biggest, becomes more difficult because of stricter regulators and patent expirations. Novartis AG in April agreed to buy a 25 percent stake in Alcon Inc. from Nestle SA for $11 billion and may acquire another 52 percent to become the world's biggest maker of eye-care products.
Sanofi-Aventis SA, France's largest drugmaker, made a $2.02 billion offer for the remainder of Zentiva NV earlier this month. The French drugmaker wants Zentiva to expand into eastern Europe's ``branded generic'' market, where copies of original treatments are more profitable than in western Europe.
``This makes a lot of sense,'' said Beatrice Kunz, a portfolio manager at Clariden Leu in Zurich who helps manage $147 billion in assets, including shares of Roche. ``The weak dollar and the fact that they are not paying a huge premium make this rather attractive.''
The purchase would be the biggest in the pharmaceuticals sector since Pfizer Inc.'s 2003 purchase of Pharmacia Corp. for about $64.3 billion in stock, according to Bloomberg data. The deal would be the biggest in the industry this year. The second- biggest so far this year is Teva Pharmaceutical Industries Ltd.'s July 18 bid to buy Barr Pharmaceuticals Inc. for $7.46 billion.
Roche's bid represents a sales multiple of about 7.45, according to Bloomberg data. That compares with a sales multiple of 4.63 in Pfizer's bid for Pharmacia.
Roche confirmed its outlook for an increase of almost 10 percent for group sales, with above-market rate growth in both its pharmaceuticals and diagnostics divisions. The forecast excludes sales of Tamiflu to governments and corporations. Roche said it expects core earnings per share to remain at least in line with the record level achieved in 2007.
The Genentech purchase would result in pretax savings of $750 million to $850 million a year and would add to EPS in the first year after closing, Roche said.
Roche is being advised by Greenhill & Co. and plans to finance the transaction through a combination of its own funds and debt. Roche's Chairman Franz Humer said he's confident the company can raise the necessary debt financing.
``We talked to a consortium of banks beforehand and I am sure the financing will not be a problem while at the same time leaving us with enough cash for further smaller and mid sized deals,'' he said in a Bloomberg interview.
The Genentech board is likely to establish an independent committee to review the offer, Roche said. Genentech board members who are employees of Roche won't participate in the evaluation of the proposal. The deal will likely be subject to approval by a majority of the owners of Genentech shares not held by Roche, the Swiss company said.
Genentech's independence has always been ``a big plus,'' Clariden Leu's Kunz said. ``If the wrong people now start leaving, there may be some problems,'' she said.
Humer said the company would continue to run under the Genentech name and retain an independent research organization.
``The diversity will remain,'' he said. ``This is not about cost-cutting but rather creating synergies. We will be saving infrastructure costs.''
The U.S. company raised its 2008 forecast July 14 as Avastin gained from the new use in breast cancer. Genentech said second- quarter profit rose 4.7 percent and revenue increased 8 percent to $3.2 billion, led by U.S. sales of Avastin. The medicine, first approved in 2004 for colon cancer and for lung malignancies two years later, is being studied against 20 tumor types worldwide.
Avastin sales in the U.S. rose 15 percent to $650 million, about $7 million more than analysts had projected. Rituxan, a treatment for non-Hodgkin's lymphoma and rheumatoid arthritis that Genentech markets with Cambridge, Massachusetts-based Biogen Idec Inc., generated $651 million, a 12 percent increase. Sales of Tarceva, used to treat lung and pancreatic cancers, gained 17 percent to $119 million.
In (litely) @ $75.9799 .... Good Morning, Serious .... !!
BusinessWeek blurb on Genentech's robust growth
High earnings (2.50 EPS for 2007)
High growth (28% out to 2010)
Low PEG, low forward P/E
Aplogies to DNA board, that was meant for PPHM board. TIA.
The deception and lies abound...
ricardo, the deceiver, misinformer and liar about
so many things...
Rico the deceiver and twister of the truth.
You prove that my friend here in Sarasota
is not in the HCV trial pig slop boy...
Tic, toc, tic, toc...waiting??
+++I would like to be the King of Siam.
Not possible, now the lil piggies are squeeling, so go back to work. Mucho el sloppo to clean up...
There will never be a Tarvacin trial...
Clinical Trial Results Show that Peregrine's First-In-Class Anti-Viral Agent Tarvacin is Safe and Well-Tolerated in HCV Patients
12-9-05 Added 5th site: Scott & White Hospital, Temple TX (PI: Dr. Lucas Wong)
10-21-05 Added 4th site: M.D.Anderson/Houston (PI: Dr. Nuhad K. Ibrahim) http://tinyurl.com/7ekld
9-2-05 Added 3rd site: Premiere Oncology/SantaMonica (PI: Dr. Lee Rosen): http://www.premiereoncology.com
1-18-06: HepC Trial "several mos. ahead of schedule" http://tinyurl. com/9dkar
9-27-05: Sarasota Herald article on Bach&Godofsky HEP-C clinic, uniquely mentioning Tarvacin P1 http://tinyurl.com/98dr4
Dr. Philip Thorpe’s lab at UTSW-MC/Dallas, Peregrine, NIAID(NIH), USAMRIID (U.S. BioDefense Res. Pgm.), and Tulane & Duke Univ's take dead aim on ALL ENVELOPED VIRUSES (ex: Hep/B+C, Influenza/Avian Flu, HIV, CMV, Pneumonia, Herpes, SARS, Ebola, Marburg, West Nile, Dengue, Lassa Fever) with Anti-Phospholipid Therapy (APT) agents, like Anti-PS/3G4/Tarvacin, which are “surprisingly effective in inhibiting the entry, replication and the spread of viral infections.”
Peregrine's Website: http://www.peregrineinc.com
http://www.peregrineinc.com/content.php?mi=NTU= TarvacinAV MOA
http://www.peregrineinc.com/content.php?mi=NjM= TarvacunAC MOA
Oh the overkill of proof and information......
and about 100X this available on IHUB.
Thanks CJG for your hard work on IHUB.com
Rico, no trials? 16 ongoing at once right now for Tarvacin and Cotara.
Lies, Lies, Lies, yeah.....oooh they're gonna
total agreement -------- one of the best of the thousands
out there !!!!!!!!!!!!!!!!
Here is more news:
Genentech Inc. signed a deal with a nonprofit foundation in Burlingame to study the use of its colorectal cancer drug Avastin as a treatment for brain cancer.
The Food and Drug Administration approved Avastin in February 2004 for colorectal cancer treatment. The drug interferes with angiogenesis, or the growth of blood vessels, in tumors. Genentech has been exploring its use for other types of cancer, including kidney, breast and ovarian.
This baby is a profit machine.
Herceptin ‘Simply Stunning’ For Breast Cancer
Oct. 20. — In the sober world of medical journals, the choice of language is unprecedented. The first trials of the breast cancer drug, Herceptin, in women with early stage disease are “simply stunning,” the New England Journal of Medicine (NEJM) says today.
They reveal “a dramatic and perhaps permanent perturbation in the natural history of the disease, maybe even a cure.” The results are, it concludes, “revolutionary, not evolutionary” adding: “Our care of patients with HER II positive breast cancer must change today.”
Medical journals rarely speak of a cure for cancer. Women treated with Herceptin had a 46 per cent reduced risk of their breast cancer returning. The drug works on patients sensitive to the protein HER II, who number 8,000 to 10,000 in the UK, 20 to 25 per cent of those newly diagnosed with the disease.
The headline results were presented at a conference in Orlando, Florida, last May, when US specialists gave the researchers a standing ovation, and are published in full for the first time today. No drug, not even tamoxifen the gold standard in breast cancer for over 30 years, has shown such a significant reduction in risk in so short a time (one to two and a half years), the journal says.
Breast cancer charities were exultant yesterday. Dr Jeremy Hughes, chief executive of Breakthrouugh Breast Cancer said: “This is one of the biggest breakthroughs in breast cancer treatment. It is vital that this drug, which is set to save around 1000 women’s lives a year, is made available on the NHS without delay.”
The results helped boost sales for Roche, the Swiss based pharmaceutical company, which reported third quarter profits up 20 per cent yesterday. Roche also makes Tamiflu, the drug being stockpiled by countries around the globe as a defence against the threatened pandemic of avian flu.
The research on Herceptin triggered a worldwide demand for the drug even before it was licensed for early breast cancer (it is currently licensed only for advanced breast cancer that has spread to other organs). The trials reported in the NEJM involved 3,000 women in the US and 5,000 women in 39 other countries who were randomly allocated to treatment with Herceptin following chemotherapy.
The discovery that Herceptin only works in certain women demonstrates that breast cancer is not one but several diseases and marks a new era in cancer research. Instead of screening thousands of compounds to find one that works — the traditional mode of drug discovery — scientists are now designing drugs to target specific receptors identified as playing a role in cancer at the molecular level.
Thursday, Mar 26, 2009
Basel, Switzerland and South San Francisco, California -- March 26, 2009 --
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech (NYSE: DNA) announced today that Roche has completed its acquisition of Genentech pursuant to a short-form merger in which Genentech became a wholly-owned member of the Roche Group. Roche had announced earlier in the day the successful completion of its tender offer, which expired on Wednesday, March 25. In connection with the merger, all remaining public shareholders will, subject to appraisal rights, receive $95.00 per share for their shares.
Genentech's common stock will no longer be traded on the New York Stock Exchange after Thursday, March 26.
Roach board is here: